CLINICAL TRIALS PROFILE FOR NSI-189
✉ Email this page to a colleague
Clinical Trials for NSI-189
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01310881 ↗ | Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189 | Completed | Neuralstem Inc. | Phase 1 | This is a subject single blinded, randomized, placebo-controlled, single dose, first-time-in-human study with three or more ascending cohorts. |
| NCT01520649 ↗ | Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects | Completed | Neuralstem Inc. | Phase 1 | This is a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation in depressed human subjects study. |
| NCT02695472 ↗ | Study of NSI-189 for Major Depressive Disorder | Unknown status | Neuralstem Inc. | Phase 2 | The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80 milligrams/day (provided as 40 milligrams twice per day), NSI-189 40 milligrams once a day, or placebo. |
| NCT02724735 ↗ | A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder | Unknown status | Neuralstem Inc. | All subjects completing the randomized treatment period in Protocol NS2014-1 will discontinue study drug and be asked to provide consent to be followed in this 6-month study, at their final safety visit. The study will consist of an enrollment visit, followed by bi-monthly in-clinic visits with monthly telephone visits between in-clinic visits. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for NSI-189
Condition Name
Clinical Trial Locations for NSI-189
Trials by Country
Clinical Trial Progress for NSI-189
Clinical Trial Phase
Clinical Trial Sponsors for NSI-189
Sponsor Name
